Source - LSE Regulatory
RNS Number : 2795S
Jounce Therapeutics, Inc.
08 March 2023
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1.             KEY INFORMATION

 

(a)  Full name of discloser:

JOUNCE THERAPEUTICS, INC.

(b)  Owner or controller of interests and short positions disclosed, if different from 1(a):

       The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c)  Name of offeror/offeree in relation to whose relevant securities this form relates:

       Use a separate form for each offeror/offeree

JOUNCE THERAPEUTICS, INC.

(d)  Is the discloser the offeror or the offeree?

OFFEROR

(e)  Date position held:

       The latest practicable date prior to the disclosure

7 MARCH 2023

(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

       If it is a cash offer or possible cash offer, state "N/A"

NO

 

2.             POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a)           Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Common Stock shares of 1/1000 dollar each in Jounce Therapeutics, Inc.

 

 

Interests

Short positions

Number

%

Number

%

(1)  Relevant securities owned and/or controlled:

Nil

0

Nil

0

(2)  Cash-settled derivatives:

 

Nil

0

Nil

0

(3)  Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

0

Nil

0

 

       TOTAL:

Nil

0

Nil

0

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b)           Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

Nil

Details, including nature of the rights concerned and relevant percentages:

Nil

 

 

3.             POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

 

(A) Interests held by The Toronto-Dominion Bank* as a concert party with Jounce Therapeutics, Inc.:

 

 

Class of relevant security:

 

USD 0.001 Common Stock

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,663,489

3.19

-

-

(2) Cash-settled derivatives:

 

-

-

1,663,489

3.19

 

     TOTAL:

1,663,489

3.19

1,663,489

3.19

 

*The Toronto-Dominion Bank acquired Cowen, Inc. on 1 March 2023, this disclosure is a continuation of Cowen, Inc. disclosures.

 

 

 

 

(B) Interests held by the directors of Jounce Therapeutics, Inc. and their close relatives and related trusts:

 

 

 

Director

No. of Common Stock shares of 1/1000 dollar each held

Percentage of issued share capital

Robert Kamen

60,975

0.11%

The Robert Kamen 2012 Irrevocable Trust

33,875

0.06%

Richard Murray

142,173

0.27%

Perry Karsen

5,000

0.00%

 

(C) Interests held as options or awards by directors of Jounce Therapeutics, Inc. under its share plans:

 

Director

Scheme

No. of Common Stock shares of 1/1000 dollar each held

Grant Date

(MMDDYYYY)

Vesting Date

Expiry Date

(MMDDYYYY)

Exercise price ($)

Robert Kamen

2013 Stock Option and Grant Plan

10,840

10/25/2016

Fully vested

10/25/2026

9.56

2017 Stock Option and Incentive Plan

13,550

06/19/2018

Fully vested

06/19/2028

7.92

2017 Stock Option and Incentive Plan

15,700

06/12/2019

Fully vested

06/12/2029

4.46

2017 Stock Option and Incentive Plan

15,700

06/26/2020

Fully vested

06/26/2030

7.58

2017 Stock Option and Incentive Plan

15,700

06/18/2021

Fully vested

06/18/2031

7.27

2017 Stock Option and Incentive Plan

20,000

06/24/2022

Fully vested

06/24/2032

2.80

Luisa Salter-Cid

2017 Stock Option and Incentive Plan

31,400

02/10/2021

February 2024 or Sale Event

02/10/2031

12.36

2017 Stock Option and Incentive Plan

7,850

06/18/2021

Fully vested

06/18/2031

7.27

2017 Stock Option and Incentive Plan

20,000

06/24/2022

June 2023 or Sale Event

06/24/2032

2.80

Robert Iannone

2017 Stock Option and Incentive Plan

31,400

01/21/2020

Fully vested

01/21/2030

7.19

2017 Stock Option and Incentive Plan

7,850

06/26/2020

Fully vested

06/26/2030

7.58

2017 Stock Option and Incentive Plan

15,700

06/18/2021

Fully vested

06/18/2031

7.27

2017 Stock Option and Incentive Plan

20,000

06/24/2022

June 2023 or Sale Event

06/24/2032

2.80

Luis A. Diaz, Jr.

2017 Stock Option and Incentive Plan

27,100

10/20/2017

Fully vested

10/20/2027

14.78

2017 Stock Option and Incentive Plan

10,163

06/19/2018

Fully vested

06/19/2028

7.92

2017 Stock Option and Incentive Plan

15,700

06/12/2019

Fully vested

06/12/2029

4.46

2017 Stock Option and Incentive Plan

15,700

06/26/2020

Fully vested

06/26/2030

7.58

2017 Stock Option and Incentive Plan

15,700

06/18/2021

Fully vested

06/18/2031

7.27

2017 Stock Option and Incentive Plan

20,000

06/24/2022

June 2023 or Sale Event

06/24/2032

2.80

Richard Murray

2013 Stock Option and Grant Plan

665,169

07/14/2014

Fully vested

07/14/2024

0.48

2013 Stock Option and Grant Plan

165,954

07/16/2015

Fully vested

07/16/2025

2.36

2013 Stock Option and Grant Plan

54,200

12/09/2015

Fully vested

12/09/2025

4.02

2013 Stock Option and Grant Plan

182,926

10/25/2016

Fully vested

10/25/2026

9.56

2017 Stock Option and Incentive Plan

200,000

02/01/2018

Fully vested

02/01/2028

23.98

2017 Stock Option and Incentive Plan

125,010

02/01/2019

Fully vested

02/01/2029

4.40

2017 Stock Option and Incentive Plan

150,010

02/03/2020

3 February 2024 or Sale Event

02/03/2030

6.55

2017 Stock Option and Incentive Plan

150,000

02/01/2021

1 February 2025 or Sale Event

02/01/2031

11.89

2017 Stock Option and Incentive Plan

15,000

02/03/2021

3 February 2025 or Sale Event

02/03/2031

12.67

2017 Stock Option and Incentive Plan

175,00

02/01/2022

1 February 2026 or Sale Event

02/01/2032

7.56

Perry Karsen

2013 Stock Option and Grant Plan

75,880

03/04/2016

Fully vested

03/04/2026

4.06

2013 Stock Option and Grant Plan

10,840

10/25/2016

Fully vested

10/25/2026

9.56

2017 Stock Option and Incentive Plan

13,550

06/19/2018

Fully vested

06/19/2028

7.92

2017 Stock Option and Incentive Plan

15,700

06/12/2019

Fully vested

06/12/2029

4.46

2017 Stock Option and Incentive Plan

15,700

06/26/2020

Fully vested

06/26/2030

7.58

2017 Stock Option and Incentive Plan

15,700

06/18/2021

Fully vested

06/18/2031

7.27

2017 Stock Option and Incentive Plan

20,000

06/24/2022

24 June 2023 or Sale Event

06/24/2032

2.80

Barbara Duncan

2013 Stock Option and Grant Plan

34,271

05/10/2016

Fully vested

05/10/2026

4.21

2013 Stock Option and Grant Plan

10,840

10/25/2016

Fully vested

10/25/2026

9.56

2017 Stock Option and Incentive Plan

13,550

06/19/2018

Fully vested

06/19/2028

7.92

2017 Stock Option and Incentive Plan

15,700

06/26/2019

Fully vested

06/12/2029

4.46

2017 Stock Option and Incentive Plan

15,700

06/26/2020

Fully vested

06/26/2030

7.58

2017 Stock Option and Incentive Plan

15,700

06/18/2021

Fully vested

06/18/2031

7.27

2017 Stock Option and Incentive Plan

20,000

06/24/2022

24 June 2023 or Sale Event

06/24/2032

2.80

Jigar Raythatha

2017 Stock Option and Incentive Plan

31,400

09/13/2021

13 September 2024 or Sale Event

09/13/2031

6.80

2017 Stock Option and Incentive Plan

20,000

06/24/2022

24 June 2023

06/24/2032

2.80

 

(D) Interests held as restricted stock units by directors of Jounce Therapeutics, Inc. under its share plans:

 

 

Restricted Stock Units, or RSUs, represent a right to receive a specified number of shares of stock at a later date (or dates) upon the grantee's satisfaction of vesting conditions. No shares are issued on the grant date and, upon vesting, shares are issued without any cost to the grantee. A grantee of RSUs has no rights as a stockholder until the vesting of the RSU and the issuance of shares. All Jounce RSU awards are subject to time-based vesting and typically vest in equal annual instalments over three years, subject to acceleration in certain circumstance; no Jounce RSU awards have performance-based vesting conditions. Jounce's standard form of RSU award is available via its public filings here.

 

 

 

Director

Scheme

No. of Common Stock shares of 1/1000 dollar each held

Grant Date

(MMDDYYYY)

Vesting Date

Expiry Date

Exercise price ($)

Richard Murray

2017 Stock Option and Incentive Plan

56,667

As to: 25,000 RSUs - 02/01/2021

2,500 RSUs - 02/03/2021; 29,167 RSUs - 02/01/2022

Earlier of 6 January 2024 or termination without cause

Earlier of 6 January 2024 or termination of employment

N/A

2017 Stock Option and Incentive Plan

29,167

02/01/2022

Earlier of 6 January 2025 or termination without cause

Earlier of 6 January 2025 or termination of employment

N/A

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4.             OTHER INFORMATION

 

(a)           Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(b)           Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i)   the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(c)           Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

8 March 2023

Contact name:

Kim Drapkin

Telephone number:

+1 (857) 999-2906

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEMZGGFRRDGFZG
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Redx Pharma PLC (REDX)

-1.00p (-10.00%)
delayed 16:15PM